Navigation Links
Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
Date:9/18/2007

umor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of RPLS in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Safety Data of VELCADE as a single-agent: In 1163 patients in multiple myeloma and mantle cell lymphoma studies, the most commonly reported adverse events were asthenic conditions (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy (39%), thrombocytopenia (36%), appetite decrease, including reports of anorexia (36%), pyrexia (34%), vomiting (33%) and anemia (29%). Twenty percent of patients re
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Hologic, Inc. ... plans to release its financial results for the third ... after the market closes.  In conjunction with the release, ... 4:30 p.m. Eastern Time. Interested participants may ... the United States ) or 719-325-4804 (for ...
(Date:7/6/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/58tdl6/pharmaceutical ) ... Sodium Chloride Market by Applications, by Region - Industry ... offering. The pharmaceutical grade sodium chloride market ... 2014 and 2019 in terms of volume, and the ... The report on Pharmaceutical grade sodium chloride ...
(Date:7/6/2015)... July 6, 2015 Array BioPharma,s (NASDAQ: ... this past weekend at the 2015 ESMO World ... At the meeting, data were shared from a ... 100-patient randomized Phase 2 expansion of that trial ... EGFR inhibitor, with or without the addition of ...
Breaking Medicine Technology:Hologic to Announce Financial Results for the Third Quarter of Fiscal 2015 on Wednesday, July 29, 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4
... , ORLANDO, Fla. , May 19 ... of medicine to their daily routine.  In 2009, drug trend ... increased 10.8 percent, driven by a 5 percent increase in ... 2010 Drug Trend Report.  The growth in prescription drug use ...
... May 19 Five presentations reporting the ... LYSTEDA™ (tranexamic acid) tablets, a novel, first-in-class, non-hormonal therapy ... bleeding (HMB), were presented at The American College of ... San Francisco , May 15-19, 2010 .  It ...
Cached Medicine Technology:New Research: Kids' Consumption of Chronic Medications on the Rise 2New Research: Kids' Consumption of Chronic Medications on the Rise 3New Research: Kids' Consumption of Chronic Medications on the Rise 4New Research: Kids' Consumption of Chronic Medications on the Rise 5Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 2Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 3Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 4Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 5Clinical Data Demonstrates That LYSTEDA™ Significantly Reduced Menstrual Blood Loss and Limitations on Social, Leisure and Physical Activities in Women With Cyclic HMB 6
(Date:7/7/2015)... ... July 07, 2015 , ... Each year the ... charitable organizations on a local, national and international level; however, the Holiday Inn now ... will have a high impact on the beneficiaries. In September of 2014 they hosted ...
(Date:7/6/2015)... ... July 06, 2015 , ... PristineHydro ( http://www.pristinewaterfilters.com ... acids, chemicals and impurities; it also properly mineralizes the water with electrolyte salts.  ... contaminants.  These harmful contaminants are a byproduct of how the water is treated ...
(Date:7/6/2015)... Hill, CA (PRWEB) , ... July 06, 2015 , ... ... Doctors on Liens , the leading network of doctors working on a lien basis. ... with Doctors on Liens. , The daughter of two Cambodian refugees, Dr. Lim suffered ...
(Date:7/6/2015)... Vancouver, BC (PRWEB) , ... July 06, 2015 , ... ... has received the UBC 2014-2015 Post Graduate Teaching Award on behalf of the department ... Endocrinology is a very exciting field to be practicing in. The technology is changing ...
(Date:7/6/2015)... ... July 06, 2015 , ... Seedstock today announced Pierre Sleiman, ... at the 4th Annual Seedstock Sustainable Agriculture Conference – “Innovation and the Small Farmer” ... held at the University of California-San Diego, will explore solutions and methodologies that small ...
Breaking Medicine News(10 mins):Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 2Health News:The Holiday Inn Westbury - Long Island Will Host a Fundraising Event on September 16th 2015 from 6:00 pm - 10:00 pm to Benefit Angela's House located on Long Island 3Health News:Pristine Water Filters.com Offers The 1st Water Revival System That Re-Mineralizes Drinking Water and Eliminates All Impurities and Chemicals 2Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 3Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 4
... CardWorks Servicing, LLC,("CardWorks") the largest privately held third ... LLC ("CMS"), announced,today that the company has been ... will partner with E-Duction, Inc., a leader in,employment-based ... one of the nation,s largest publicly traded health ...
... research shows proteins from the reptiles can fight off ,superbugs, ... case of gator aid. New research suggests that alligator blood ... caused by ulcers, burns and even drug-resistant "superbugs." , The ... blood have only been tested in the laboratory -- and ...
... crisis in science education, scientific research, and the role science should ... ... -, NEW YORK, April 7, 2008 Since its launch in ... complex,science and human health issues facing the 21st century, including the,brain, the ...
... EDMOND, Okla., April 7, 2008 Edmond Medical Center ... M.D. of,Edmond Regional Eye Associates, will once again participate ... free cataract surgeries,for those who cannot afford to pay., ... at the physicians,office. If the patient qualifies for the ...
... April 7, 2008 Principals announced today a ... asbestos claims with,chemical manufacturer W.R.Grace & Co. and ... to emerge from bankruptcy,with no further obligations for ... 1938 until the 1970,s., Terms of the ...
... PHILADELPHIA, April 7, 2008 Schoolchildren,who required surgery ... a,significant risk of having problems with inattention and ... children are at risk for,academic and behavior problems, ... provide them with ongoing follow-up and neurodevelopmental,screening," said ...
Cached Medicine News:Health News:CardWorks Named Servicer of Choice for Innovative Credit Card for Healthcare Services 2Health News:CardWorks Named Servicer of Choice for Innovative Credit Card for Healthcare Services 3Health News:Gator Blood May Be New Source of Antibiotics 2Health News:Gator Blood May Be New Source of Antibiotics 3Health News:Charlie Rose Science Series Wraps Up With Episode on 'The Imperative and Promise of Science' 2Health News:Charlie Rose Science Series Wraps Up With Episode on 'The Imperative and Promise of Science' 3Health News:Edmond Medical Center to Provide Free Cataract Surgeries 2Health News:$3 Billion Asbestos Deal Reached by W.R.Grace Company to Pay Asbestos Victims 2Health News:For Children With Heart Disease, a Risk of Attention and Behavior Problems 2
... A necessary addition to ... the Reichert Trial Frame ... and smooth controls for ... robust design, high-quality materials, ...
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
... Illumination is provided by a cool-running, energy ... only what you need to see without ... of all they are maintenance free so ... bulb. Every Phoroptor comes with a limited ...
Medicine Products: